Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 37,940	$ 26,676
Short-term investments – available for sale	813,918	875,936
Prepaid clinical trial and preclinical study costs	13,300	3,476
Prepaid expenses and other current assets	865	1,128
Total current assets	866,023	907,216
Right-of-use assets	892	1,003
Deferred financing costs	32	56
Deposits	46	46
Total assets	866,993	908,321
Current liabilities:
Accounts payable	7,702	9,813
Other accrued liabilities	11,373	17,111
Lease liability, current	498	489
Total current liabilities	19,573	27,413
Lease liability, net of current portion	502	630
Total long-term liabilities	502	630
Total liabilities	20,075	28,043
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 112,288,759 shares issued and outstanding at March 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024	1	1
Treasury stock at cost, no shares at March 31, 2025 and December 31, 2024	0	0
Additional paid-in capital	1,380,669	1,368,972
Accumulated deficit	(533,536)	(487,907)
Accumulated other comprehensive loss	(216)	(788)
Total stockholders’ equity	846,918	880,278
Total liabilities and stockholders’ equity	$ 866,993	$ 908,321